High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
- Fabricante: DEWAEL
- Ensayo del producto: 99%+
- Apariencia:Polvo cristalino blanco.
- Lugar de origen: China
- Proceso de dar un título: SGS,ISO9001, GMP
- Cantidad mínima de pedido: 10sol
- detalles del empaque: 1 kg/bolsa de aluminio,25kg/drum or as your requirements
- El tiempo de entrega: Dentro 12 horas después de recibir su pago
- Términos de pago: Western Union, MoneyGram,Bitcoin,Transferencia bancaria
- Envío: ccsme,DHL,Federal Express,UPS,TNT y así sucesivamente.
- Política: Re-envío Política
- capacidad de la fuente: 500-600kg / mes
High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
Detalles:
Rimonabant hydrochloride
nombre del producto: Rimonabant hydrochloride
sinónimos: RIMONABANT HYDROCHLORIDE;5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride;ACOMPLIA;ACOMPLIA (RIMONABANT;RIMONABANT HCL;Rimonabant(Acomplia);RimonabantConsultedStandard;Acomplia, SR141716
CAS: 158681-13-1
MF: C22H21Cl3N4O.ClH
MW: 500.25
Chemical Properties White to Off-White Crystalline Solid
Usage The first of a new class of selective (Cannabinoid-1 (CB-1) receptor antagonists
Usage A brain cannabinoid receptor (CB1) antagonist. Antiobesity agent.
COA:
|
Nombre del producto
|
Rimonabant
|
|||
|
CAS No.
|
168273-06-1 |
Outer Packing
|
1kg/bag | |
|
Production date
|
May 14th. 2018 |
Duración
|
May 13th. 2020 | |
|
Products Standard
|
Estándar de la empresa | |||
|
Items of analysis
|
Especificación
|
resultados
|
||
| Assay by (HPLC) | 99%-101% | 99.43% | ||
| Characters/appearance | White to off White powder | Cumple | ||
| Odor and taste | Odorless | Cumple | ||
| Identificación | Positive reaction | Cumple | ||
| Mesh size/sieve analysis | 100% pass 80 mesh | Cumple | ||
| Pérdida por secado | 1% Max | 0.78% | ||
| Water | ≤2.0% | 0.1% | ||
| Residuo de ignición | 01%Max | Cumple | ||
| Single impurity | 0.1% Max | Cumple | ||
| Malting point | 272.25 ºC | Cumple | ||
| Bolling point | 627 .69 ºC | Cumple | ||
| Refractive Index | N20O1.67 | Cumple | ||
| PH | 50-7.0 | 6.5 | ||
| pK Values | pK. 11.31(Predicted). pK„ 3. 22 (Predicted) | Cumple | ||
| Solubilidad | Soluble in ethanol (-20 mg / ml). DMSO (25 mg / ml) .DMF (-20mg / ml). and water (< 1 mg / ml) | Cumple | ||
| Metales pesados | NMT 10ppm | Cumple | ||
| Microbiological Control | 78cfu/g | 78cfu/g | ||
| Total Plate Count | 1000 cfu/g Max | Negative | ||
| Fungi | <100/sol | Negative | ||
| Salmonella | Negative | Negative | ||
| Coll | negative | negative | ||
|
Conclusión
|
Qualified | |||
Rimonabant Description:
(1). Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 Nuevo Méjico, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
(2). Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
(3). It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Rimonabant Applications:
(1). Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
(2). Rimonabant hydrochloride also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.
———————————————————————————————————————————————————————————————————————————————————————-
Contacta ahora
Comentarios
No hay comentarios aún.